[Multimodality treatment outcome of invasive thymomas].
The aim of the study was to analyze the progression of invasive thymomas associated with myasthenia gravis, after the resection and the progression of unresectable invasive thymomas with a combined chemoradiotherapy. The study was performed on two groups of patients: 8 patients with invasive thymomas and myasthenia gravis operated at the 3rd Surgical Clinic between 1986-1999; 4 patients with unresectable invasive thymomas treated at the Radiology-Oncology Clinic by combined chemoradiotherapy, between 1993-1998. The results are presented for each group of patients, separately.


CONCLUSIONS
The best treatment of invasive thymomas is the multimodal one. The timing of each method was established based on the collaboration between surgeons, medical oncologists, radiotherapists and neurologists, depending on the characteristics of each patient.
Andriescu
L
L
Facultatea de Medicină, Clinica a III-a Chirurgie, Universitatea de Medicina şi Farmacie Gr.T. Popa, Iaşi.
Buiuc
A I
AI
Dolinescu
C
C
Dragomir
C
C
Albulescu
E
E
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012189:Retrospective Studies; D013945:Thymoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*